Phase II trial of ipilimumab in melanoma patients with preexisting humoural immune response to NY-ESO-1
Haag, G. M., Zoernig, I., Hassel, J. C., Halama, N., Dick, J., Lang, N., Podola, L., Funk, J., Ziegelmeier, C., Juenger, S., Bucur, M., Umansky, L., Falk, C. S.
, Freitag, A., Karapanagiotou-Schenkel, I., Beckhove, P., Enk, A. and Jaeger, D.
(2018)
Phase II trial of ipilimumab in melanoma patients with preexisting humoural immune response to NY-ESO-1.
European Journal of Cancer 90, pp. 122-129.
Date of publication of this fulltext: 28 Jul 2021 17:23
Article
Alternative links to fulltext
Involved Institutions
Details
| Item type | Article | ||||
| Journal or Publication Title | European Journal of Cancer | ||||
| Publisher: | Elsevier | ||||
|---|---|---|---|---|---|
| Place of Publication: | OXFORD | ||||
| Volume: | 90 | ||||
| Page Range: | pp. 122-129 | ||||
| Date | 2018 | ||||
| Institutions | Leibniz Institute for Immunotherapy (LIT) | ||||
| Identification Number |
| ||||
| Keywords | Melanoma; Immunotherapy; Ipilimumab; Cancer/testis antigen; NY-ESO-1 | ||||
| Dewey Decimal Classification | 600 Technology > 610 Medical sciences Medicine | ||||
| Status | Published | ||||
| Refereed | Yes, this version has been refereed | ||||
| Created at the University of Regensburg | Partially | ||||
| Item ID | 47522 |
Export bibliographical data
Owner only: item control page
Altmetric
Altmetric